

Andrew J Cooper

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7671944/andrew-j-cooper-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9

papers

12

citations

2

h-index

3

g-index

10

ext. papers

25

ext. citations

4.5

avg, IF

0.45

L-index

#	Paper	IF	Citations
9	Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2022 , 185, 109218	7.4	0
8	Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1956-1960	6.7	2
7	324-OR: Global Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER. <i>Diabetes</i> , 2021 , 70, 324-OR	0.9	1
6	Type 2 diabetes and heart failure: insights from the global DISCOVER study. <i>ESC Heart Failure</i> , 2021 , 8, 1711-1716	3.7	6
5	Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2021 , 178, 108947	7.4	0
4	What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2336-2343	6.7	1
3	Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2021 , 180, 108974	7.4	1
2	1598-P: HbA1c. <i>Diabetes</i> , 2020 , 69, 1598-P	0.9	
1	1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study. <i>Diabetes</i> , 2020 , 69, 1590-P	0.9	